Clinical Trial

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single arm, phase II study without blinding. The purpose is to determine the impact of hepatic artery infusion Floxuridine (FUDR) on liver metastases from pancreatic adenocarcinoma. Patients at Spectrum Health will receive standard of care chemotherapy. They will also receive chemotherapy via surgically placed hepatic artery infusion (HAI) pump.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2019-02-25; most recent amendment 2026-07-15.
Status change: Recruiting → Active, Not Recruiting 2024-12-10
Trial Details
NCT Number NCT03856658
Lead Sponsor Corewell Health West
Conditions Pancreatic Adenocarcinoma, Liver Metastases
Enrollment 14 participants
Start Date 2019-02-05
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-16